Hapvida Participacoes e Investimentos (HAPV3) Q3 2024 earnings summary

Executive summary

• Net revenue for Q3 2024 grew 6.6% year-over-year to R$7,338 million, driven by a 9.6% increase in average ticket and price adjustments, despite a slight decline in beneficiaries.

• Adjusted EBITDA for Q3 2024 was R$763 million (10.4% margin), up 2.8% year-over-year, with margin gains from cost control and verticalization.

• Adjusted net income for Q3 2024 was R$324.5 million, up R$63.5 million year-over-year; for 9M24, adjusted net income surged 156.3% year-over-year.

• Margin recovery strategies and verticalization led to a 0.1 p.p. sequential and 1.5 p.p. year-over-year improvement in cash MLR, reaching 70.4%.

• Healthy cash flows enabled deleveraging, with net debt reduced to R$4,077.5 million (0.97x EBITDA), and increased capital expenditures in network expansion.

Financial highlights

• Net revenue for 9M24 reached R$21,480 million, up 5.0% year-over-year.

• Free cash flow in Q3 2024 was R$471.5 million, with cash generation at 91.9% of Adjusted EBITDA.

• CapEx for Q3 2024 was R$180.7 million, focused on IT and healthcare infrastructure, with 2024 projection between R$700–800 million.

• Net financial expense improved to R$261.7 million in Q3 2024, down R$109.7 million year-over-year.

• Net debt/EBITDA dropped below 1x for the first time in 11 quarters, reaching 0.97x.

Outlook and guidance

• Management focuses on margin recovery, cost control, and portfolio optimization, with ongoing investments in network expansion and IT.

• Expect continued deleveraging and capital structure optimization following the recent R$2.0 billion debenture issuance.

• Anticipate a return to a neutral cycle within three to four quarters, assuming current initiatives are effective.